These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Hepatitis C: new treatment overview.
    Author: Stoia J.
    Journal: AIDS Treat News; 1998 Sep 04; (302):5-6. PubMed ID: 11365763.
    Abstract:
    Hepatitis C (HCV) affects 4 million Americans and 40 percent of HIV patients, many of whom do not know they are infected. Most of the liver transplants performed in this country are a result of HCV infections. Only one drug, alpha interferon, had been approved to treat HCV, and it is costly and ineffective. However, the FDA recently approved Schering-Plough's REBETRON, which contains injectable alpha interferon and oral doses of Ribavirin in a single "bundled" package. Ribavirin had been approved throughout the world as a broad spectrum antiviral, but its approval in the U.S. was delayed due to questions about its usefulness in treating HIV. Schering-Plough has been criticized for bundling the two drugs. The American Foundation for AIDS Research (AMFAR) is conducting the first study of Ribavirin and alpha interferon for treating HCV in people who are co-infected with HIV. Information is included regarding how to obtain several papers on these drugs.
    [Abstract] [Full Text] [Related] [New Search]